NASDAQ$TNYA
Tenaya Therapeutics Inc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Reported second quarter 2023 financial results and provided a business update.
Tenaya Therapeutics reported financial results for the second quarter ended June 30, 2023. The company's cash, cash equivalents and investments were $151.6 million as of June 30, 2023, expected to fund operations into the first half of 2025. The company anticipates dosing its first patient in the Phase 1b trial of TN-201 during the third quarter of 2023 and plans to submit an IND application for TN-401 in the second half of 2023.
- Dosing of first patient in Phase 1b trial of TN-201 on track to occur in Q3 2023.
- Data from Phase 1 clinical trial of TN-301 accepted for presentation at HFSA 2023.
- IND Application for TN-401 anticipated in second half 2023.
- Second Quarter Cash and Investments of $151.6 Million; Runway to Fund Operations into First Half 2025.
Headline financials
Revenue & EPS history
Tenaya Therapeutics · Revenue · Quarterly
$225K
Forward guidance
Tenaya expects current cash, cash equivalents and investments in marketable securities will be sufficient to fund the company into the first half of 2025.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q2 2023
+2.8%
Avg return
Earnings day
+2.1%
Avg return
5 days after
-5.6%
Avg return
30 days after
50%
9 / 18 earnings
Positive
+39.8%
Q3 2022
Best reaction
-18.7%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.8% | +30.3% | -4.2% | |
| Q4 2025 | -1.3% | -0.2% | -19.7% | |
| Q3 2025 | -1.4% | -7.0% | -4.9% | |
| Q1 2025 | +7.8% | -3.3% | +38.2% | |
| Q4 2024 | -6.5% | -12.7% | -38.4% | |
| Q3 2024 | +17.4% | +20.7% | +68.1% | |
| Q1 2024 | -0.7% | +8.9% | -12.6% | |
| Q4 2023 | -8.9% | -5.1% | -13.6% | |
| Q3 2023 | -7.8% | -10.2% | -2.9% | |
| Q2 2023 | +7.3% | +0.0% | -24.6% | |
| Q1 2023 | +12.1% | +7.2% | +9.0% | |
| Q4 2022 | -18.7% | -20.6% | -25.9% | |
| Q3 2022 | +39.8% | +53.4% | +11.0% | |
| Q2 2022 | +1.5% | +6.5% | -11.3% | |
| Q1 2022 | -5.7% | -6.7% | -29.9% | |
| Q4 2021 | +6.0% | +3.2% | -5.0% | |
| Q3 2021 | +7.7% | -13.5% | -28.1% | |
| Q2 2021 | -2.8% | -12.6% | -6.5% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro